14,786 Shares in Soleno Therapeutics, Inc. $SLNO Bought by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 14,786 shares of the company’s stock, valued at approximately $1,000,000.

Several other institutional investors and hedge funds also recently made changes to their positions in SLNO. Raymond James Financial Inc. purchased a new position in Soleno Therapeutics during the second quarter worth about $25,000. Nisa Investment Advisors LLC lifted its position in shares of Soleno Therapeutics by 287.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after buying an additional 400 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Soleno Therapeutics by 97.7% in the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after buying an additional 423 shares during the last quarter. KBC Group NV bought a new position in shares of Soleno Therapeutics in the second quarter valued at approximately $77,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Soleno Therapeutics during the second quarter valued at approximately $113,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on SLNO. The Goldman Sachs Group set a $125.00 price objective on Soleno Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $106.00 price objective (down previously from $123.00) on shares of Soleno Therapeutics in a research report on Wednesday, November 5th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Finally, Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a research note on Monday, January 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $109.23.

Soleno Therapeutics Stock Performance

NASDAQ SLNO opened at $42.48 on Monday. The firm has a market cap of $2.28 billion, a P/E ratio of -23.09 and a beta of -3.12. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. The company’s 50 day moving average is $47.58 and its 200-day moving average is $62.43. Soleno Therapeutics, Inc. has a 12-month low of $39.43 and a 12-month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.08 by $0.39. The business had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million. Sell-side analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.